← All Sponsors
SPONSOR

EyePoint Pharmaceuticals, Inc.

Total Trials
1
Recruiting
1
Phases
Phase 3
Conditions studied: Diabetic Macular EdemaDMEDiabetic Macular Edema (DME)
NCT07449923 Phase 3
Recruiting

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Diabetic Macular Edema
United States View Trial →